Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca : Results From Imfinzi Head and Neck Cancer Trial Negative

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2018 | 02:31am EDT

By Carlo Martuscelli

AstraZeneca PLC (AZN.LN) on Friday announced negative results from a phase 3 clinical trial of its cancer drug Imfinzi as a treatment for recurrent or metastatic head and neck squamous cell carcinoma.

The company said neither Imfinzi alone, nor Imfinzi plus add-on therapy tremelimumab, increased overall survival for treated patients when compared with standard-of-care chemotherapy, missing the primary objective in the Eagle trial. The patients enrolled in study had previously had their disease advance following platinum-based chemotherapy.

The Anglo-Swedish pharmaceutical said that while the results were disappointing, it remained committed to evaluating Imfinzi as a potential medicine for patients with head and neck cancer.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA 0.42% 733.5 Delayed Quote.8.88%
ASTRAZENECA 1.19% 5938 Delayed Quote.1.11%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
05/22LONDON STOCK EXCHANGE : Brexit worries hit domestic stocks but sterling slide li..
RE
05/22ASTRAZENECA : Bob Harper and AstraZeneca Expand Survivors Have Heart Initiative ..
BU
05/20ASTRAZENECA : FASENRA® (benralizumab) reduces oral corticosteroid use and mainta..
BU
05/20ASTRAZENECA : New data show Symbicort reduces attacks in mild asthma when used a..
PU
05/16ASTRAZENECA : New data on Symbicort as a potential anti-inflammatory reliever in..
PU
05/16ASTRAZENECA : continues to redefine cancer treatment at the 2019 ASCO Annual Mee..
PU
05/10Exporters lead FTSE 100 lower after dollar dips on trade hopes
RE
05/10Forty Seven to Work With AstraZeneca's Acerta in Lymphoma Study
DJ
05/10AstraZeneca Safety Analyses for Roxadustat Show Top-Line Results
DJ
05/10ASTRAZENECA : Pooled analyses of the roxadustat global Phase III
AQ
More news
Financials ($)
Sales 2019 23 580 M
EBIT 2019 6 339 M
Net income 2019 3 075 M
Debt 2019 12 321 M
Yield 2019 3,71%
P/E ratio 2019 35,36
P/E ratio 2020 26,07
EV / Sales 2019 4,72x
EV / Sales 2020 4,30x
Capitalization 98 962 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 85,3 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Shriti Vadera Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA1.11%97 161
JOHNSON & JOHNSON7.03%367 513
PFIZER-4.54%231 237
ROCHE HOLDING LTD.9.70%226 519
NOVARTIS12.54%207 417
MERCK AND COMPANY4.04%203 088